Description:
The intent of this session is to provide an open forum to explore how Quality by Design (QbD) is being implemented throughout the pharmaceutical industry. Scientists are increasingly integrating QbD principles and practices to produce more robust, higher quality drug products that are safer and more effective. QbD principles can be utilized at various stages of the manufacturing process, from understanding the impacts of incoming API and excipient raw material attributes, through blending and intermediate unit operations, to dosage form finalization. QbD is just as critical for implementation of established technologies, such as spray drying, granulation, direct compression, or capsule filling, to relatively new technologies, such as hot-melt extrusion, continuous granulation, or 3-D printing. Scientists developing small-molecule or macromolecular drug products and utilizing QbD principles to design robust processes and products are encouraged to submit abstracts.
Sponsor:
Pharmaceutical Discovery, Development and Manufacturing Forum
Co-Sponsor(s):
Pharmaceuticals (15B)
Chair:
Yong Hu
FDA CDER
Office of Process and Facilities, Office of Pharmaceutical Quality
Silver Spring, MD
Email: Yong.Hu@FDA.HHS.GOV
FDA CDER
Office of Process and Facilities, Office of Pharmaceutical Quality
Silver Spring, MD
Email: Yong.Hu@FDA.HHS.GOV
Co-Chair:
Ingmar Nopens
Associate Professor
Ghent University
BIOMATH, Dept. of Mathematical Modeling, Statistics and Bioinformatics
Ghent
9000
Email: ingmar.nopens@ugent.be
Associate Professor
Ghent University
BIOMATH, Dept. of Mathematical Modeling, Statistics and Bioinformatics
Ghent
9000
Email: ingmar.nopens@ugent.be
Papers:
Abstract Submissions Closed
See more of this Group/Topical: Pharmaceutical Discovery, Development and Manufacturing Forum
